Investigational drug · Phase 3
JMT101
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Local Advanced or Metastatic NSCLC, Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
12
Any phase or sponsor naming "JMT101"
First trial start
2021
Nov 21, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JMT101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Local Advanced or Metastatic NSCLC
- Recurrent or Metastatic Nasopharyngeal Cancer
- Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
- Metastatic Colorectal Cancer (mCRC)
- Locally Advanced or Metastatic Non-squamous NSCLC
- Harboring EGFR Sensitive Mutations NSCLC
- Previously Untreated Systematically NSCLC
- Squamous Cell Non-small Cell Lung Cancer
- Harboring EGFR Common Mutation
- Head and Neck Squamous Cell Carcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JMT101" as an intervention, largest first.
- Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT06319313 · 534 participants (planned) · Start May 1, 2024 · Primary completion Jul 1, 2026
Drug: JMT101; docetaxel and 1 more · For: Squamous Cell Non-small Cell Lung Cancer
Shanghai JMT-Bio Inc.Industry
NCT06735391 · 516 participants (planned) · Start Oct 23, 2024 · Primary completion Sep 30, 2026
Drug: JMT101; Osimertinib · For: Locally Advanced or Metastatic Non-squamous NSCLC; Harboring EGFR Sensitive Mutations NSCLC; Previously Untreated Systematically NSCLC
Sites: Guangzhou, China
- SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCCPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT06989671 · 430 participants (planned) · Start Aug 30, 2025 · Primary completion Dec 30, 2027
Drug: JMT101; SYS6002 and 1 more · For: Head and Neck Squamous Cell Carcinoma
- JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT06380348 · 398 participants (planned) · Start Apr 26, 2024 · Primary completion Mar 26, 2027
Drug: JMT101 Injection; Osimertinib tablet and 2 more · For: Local Advanced or Metastatic NSCLC
Shanghai JMT-Bio Inc.Industry
NCT04689100 · 259 participants (planned) · Start Apr 11, 2017 · Primary completion Dec 31, 2021
Drug: JMT101; JMT101 · For: Advanced Solid Tumor
Sites: Beijing, China; Bengbu, China; Changzhou, China · 9 sites in all
- The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal CancerPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT07134205 · 252 participants (planned) · Start Oct 1, 2025 · Primary completion Jun 1, 2027
Drug: JMT101; Irinotecan and 1 more · For: Metastatic Colorectal Cancer (mCRC)
- JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common MutationsActive, not recruiting
Shanghai JMT-Bio Inc.Industry
NCT06391944 · 161 participants · Start Nov 21, 2021 · Primary completion May 17, 2023
Drug: JMT101 Injection; Osimertinib tablet · For: Local Advanced or Metastatic NSCLC; Harboring EGFR Common Mutation
Sites: Beijing, China
- Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung CancerStatus unknown
Shanghai JMT-Bio Inc.Industry
NCT05132777 · 155 participants (planned) · Start Nov 20, 2021 · Primary completion Sep 30, 2023
Drug: JMT101; Osimertinib Mesylate Tablets · For: Locally Advanced or Metastatic Non-Small Cell Lung Cancer; EGFR Exon20 Insertion Mutations
- JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal CancerPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT06892431 · 150 participants (planned) · Start Apr 1, 2025 · Primary completion Dec 31, 2025
Drug: Mitoxantrone Hydrochloride Liposome; JMT101 injection and 3 more · For: Recurrent or Metastatic Nasopharyngeal Cancer; Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
- A Study of JMT101 in Patients With Metastatic Colorectal CancerPivotal-lookingStatus unknown
Shanghai JMT-Bio Inc.Industry
NCT06089330 · 102 participants (planned) · Start Jan 2024 · Primary completion Jul 2024
Drug: JMT101; SG001 and 2 more · For: Metastatic Colorectal Cancer (mCRC)
Newest research
PubMed records naming it or its code names, newest first.
- Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer.
Zhao S, Zhuang W, Han B, et al. · Nat Commun 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.